No Data
No Data
No Data
No Data
No Data
Getting In Cheap On Haemonetics Corporation (NYSE:HAE) Might Be Difficult
With a price-to-earnings (or "P/E") ratio of 33.8x Haemonetics Corporation (NYSE:HAE) may be sending very bearish signals at the moment, given that almost half of all companies in the United States ha
Simply Wall StApr 17 10:09 ET
Express News | NYSE Order Imbalance 50408.0 Shares on Sell Side
Moomoo 24/7Apr 12 15:50 ET
Haemonetics Is Maintained at Outperform by Barrington Research
Haemonetics Is Maintained at Outperform by Barrington Research
Dow JonesApr 12 10:53 ET
Barrington Research Maintains Outperform on Haemonetics, Maintains $105 Price Target
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and maintains $105 price target.
BenzingaApr 12 10:43 ET
Haemonetics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/12/2024 22.12% Barrington Research $105 → $105 Maintains Outperform 02/13/2024 22.12% Barrington Resear
BenzingaApr 12 10:42 ET
Haemonetics Poised for Growth With Strong Q4 Projections and Strategic Acquisitions
TipRanksApr 12 09:15 ET
Billy Badass : missed BBBY up 12%
71551488 Billy Badass: they dont want to promote it anymore, they probably got puts on
RDK79 : Netflix should sue the crap out of Bloomberg! These unsubstantiated postings by financial ‘experts’ without any accountability is amazing. Wall-street is bulletproof
HereForTheTrades RDK79: P/E is still 20, tell me what's reasonable for a company that struggles to increase earnings
No Data
No Data